OSE2101

OSE2101 is a cancer vaccine developed by OSE Immunotherapeutics. Its targets are HER2, CEACAM5 and TP53 (the sponsor names P53, HER-2, CEA, MAGE-2, MAGE-3 (HLA-A2-restricted epitopes) plus PADRE pan-HLA-DR epitope). The sponsor states: A peptide vaccine composed of nine HLA-A2-restricted tumour-associated antigen epitopes plus one pan-HLA-DR binding epitope, emulsified in Montanide ISA 51 adjuvant, that activates tumour-specific T lymphocytes. ClinicalTrials.gov describes the intervention as: OSE2101 is a peptidic cancer vaccine composed of nine epitopes restricted to HLA-A2 phenotype targeting the tumour associated antigens of P53, HER-2, CEA, MAGE-2 and MAGE-3, and one pan-HLA DR binding epitope (PADRE), all epitopes emulsified. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06472245 (Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor), in non-small-cell lung cancer. The largest, NCT06472245, plans to enrol 363 participants with primary completion expected 2027-12-15. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.